Effect of Changes in Liver Blood Flow on the Pharmacokinetics of Saruplase in Patients with Acute Myocardial Infarction

Summary

Background: The recombinant unglycosylated single chain urokinase-type plasminogen activator saruplase is cleared for a large part by the liver. A large interindividual variation in saruplase concentration is found in acute myocardial infarction (AMI) patients. The variable cardiac performance after an infarct may induce differences in liver blood flow that could explain the concentration diversity. This study was performed to investigate the relation between hepatic blood flow and the pharmacokinetic and pharmacodynamic properties of saruplase.

Methods and Results: Thirteen AMI patients were enroled in this open label study. Patients received a bolus injection of 20 mg saruplase followed by a one-hour infusion of 60 mg saruplase. Concurrently 36 mg intravenous indocyanine green (ICG) was given over 1 h to measure hepatic blood flow. Blood samples were taken at regular time intervals to measure plasma levels of urokinase-type plasminogen activator (u-PA) antigen and activity, the two-chain form (tcu-PA) activity, indocyanine green, fibrinogen, fibrin and fibrin degradation products, α₂-antiplasmin and thrombin antithrombin III complex. A correlation was seen between the clearance of ICG and both those of u-PA antigen (r = 0.62; p <0.05) and u-PA activity (r = 0.57; p <0.05). A negative correlation was seen between the area under the curve of tcu-PA activity and the areas under the effect curves of both fibrinogen and α₂-antiplas-min (r = -0.84; p <0.01 and r = -0.65; p <0.05).

Conclusions: Liver blood flow is an important determinant of the clearance of u-PA antigen and activity and reduction of flow in patients with heart failure will lead to an increase in plasma concentrations. High plasma concentrations of tcu-PA activity lead to increased systemic fibrinogenolysis. These results may be used to optimize saruplase treatment in patients with impaired cardiac function or after co-medication with drugs that affect liver blood flow.

• References

• 1 Meyer J, Bar F, Barth H, Charbonnier B, El DeebMF, Erbel R. PRIMI Trial Study Group. Randomised double-blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet 1989; 01: 863-868
• 2 Collen DC, Gold HK. New developments in thrombolytic therapy. Thromb Res 1990; Suppl X 105-131
• 3 Diefenbach C, Erbel R, Pop T, Mathey D, Schofer J, Hamm C, Ostermann H, Schmitz-Hubner U, Bleifeld W, Meyer J. Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction. Am J Cardiol 1988; 61: 966-970
• 4 Lijnen HR, Zamarron C, Blaber M, Winkler ME, Collen D. Activation of plasminogen by pro-urokinase; I. Mechanism. J Biol Chem 1986; 261: 1253-1258
• 5 Collen D, Zamarron C, Lijnen HR, Hoylaerts M. Activation of plasminogen by pro-urokinase; II. Kinetics. J Biol Chem 1986; 261: 1259-1266
• 6 Holmes WE, Pennica D, Blaber M, Rey MW, Guenzler WA, Steffens GJ, Heyneker HL. Cloning and expression of the gene for pro-urokinase in Escherichia coli. Bio/Technology 1985; 03: 923-929
• 7 Kohler M, Sen S, Miyashita C, Hermes R, Pindur G, Heiden M, Berg G, Morsdorf S, Leipnitz G, Zeppezaner M, Schieffer H, Wenzel E, Schonberger A. Hollemeyer K. Half-life of single-chain urokinase-type plasminogen activator (scu-PA) and two-chain urokinase-type plasminogen activator (tcu-PA) in patients with acute myocardial infarction. Thromb Res 1991; 62: 75-81
• 8 Kuiper J, Rijken DC, de Munk GAW, van Berkel TJC. In vivo and in vitro interaction of high and low molecular weight single chain urokinase-type plasminogen activator with rat liver cells. J Biol Chem 1992; 267: 1589-1595
• 9 Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Johns JA, Collen D. Dose-dependent thrombolysis, pharmacokinetics and hemostatic effects of recombinant human tissue-type plasminogen activator for coronary thrombosis. Am J Cardiol 1986; 58: 673-679
• 10 Einarsson M, Smedsrod B, Pertoft H. Uptake and degradation of tissue plasminogen activator in rat liver. Thromb Haemost 1988; 59: 474-479
• 11 Bax NDS, Tucker GT, Woods HF. Lignocaine and indocyanine green kinetics in patients following myocardial infarction. Br J Clin Pharmac 1980; 10: 353-361
• 12 Zito RA, Reid PR. Lidocaine kinetics predicted by indocyanine green clearance. New Engl J Med 1978; 298: 1160-1163
• 13 Koster RW, Cohen AF, Hopkins GR, Beier H, Günzler WA, Van der WouwPA. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 1994; 71: 740-744
• 14 Caesar J, Shaldon S, Chiandussi L, Guevara L, Sherlock L. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. Clin Sci 1961; 21: 43-57
• 15 Leevy CM, Mendenhall CL, Lesko W, Howard MM. Estimation of hepatic blood flow with indocyanine green. J Clin Invest 1962; 41: 1169-1179
• 16 Meijer DKF, Weert B, Vermeer GA. Pharmacokinetics of biliary excretion in man. VI. Indocyanine green. Eur J Clin Pharmacol 1991; 35: 295-303
• 17 Bums E, Ball CE, Christie JP, Broadhead GD, Tucker GT, Bax NDS. Direct and indirect measurement of the hepatic extraction ratio of indocyanine green in the rat. Br J Clin Pharmac 1989; 76: 503-508
• 18 Killip T, Kimball JT. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967; 20: 457
• 19 Günzler WA, Beier H, Flohé L. Activity and antigen of saruplase and twochain urokinase related plasminogen activator stabilized by a combination of aprotonin and benzamidine in citrated plasma. Fibrinolysis 1990; 04 Suppl 02 145-147
• 20 Rappaport PL, Thiessen JJ. High-pressure liquid chromatographic analysis of indocyanine green. J Pharm Sci 1982; 71: 157-161
• 21 Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-246
• 22 Stump DC, Califf RM, Topol EJ, Sigmon K, Thornton D, Masek R, Anderson L, Collen D. Pharmacodynamics of thrombolysis with recombinant tissue-type plasminogen activator. Correlation with characteristics of and clinical outcomes in patients with acute myocardial infarction. Circulation 1989; 80: 1222-1230
• 23 Bode C, Schoenermark S, Schuler G, Zimmermann R, Schwarz F, Kuebler W. Efficacy of intravenous prourokinase and a combination of prourokinase and urokinase in acute myocardial infarction. Am J Cardiol 1988; 61: 971-974
• 24 Erlemeier H-H, Zangemeister W, Burmester L, Schofer J, Mathey D, Bleifeld W. Bleeding after thrombolysis in acute myocardial infarction. Eur Heart J 1989; 10: 16-23
• 25 Gimple LW, Gold HK, Leinbach RC, Coller BS, Werner W, Yasuda T, Johns JA, Ziskind AA, Finkelstein D, Collen D. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation 1989; 80: 581-588
• 26 Okazaki K, Miyazaki M, Onishi S, Ito K. Effects of food intake and various hormones on portal blood flow in patients with liver cirrhosis demonstrated by pulsed Doppler with the Octoson. Scand J Gastroenterol 1986; 21: 1029-1038
• 27 van Griensven JMT, Burggraaf J, Gerloff J, Günzler WA, Beier H, Kroon JM, Huisman LGM, Schoemaker HC, Kluft C, Cohen AF. The influence of changes in liver blood flow on the kinetics and dynamics of single chain urokinase-type plasminogen activator in healthy volunteers. Br J Clin Pharmac 1994; 37: 485 P
• 28 GISSI-3 Collaborative Group. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate single and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-1122
• 29 ISIS-4 Collaborative Group. Fourth international study of infarct survival: Protocol for a large study of the effects of oral mononitrate, oral captopril, and of intravenous magnesium. Am J Cardiol 1991; 68: 087 D-100 D
• 30 Geneve J, Le Dinh T, Brouard A, Bails M, Segrestaa JM, Caulin C. Changes in indocyanine green kinetics after the administration of enalapril to healthy subjects. Br J Clin Pharmac 1990; 30: 297-300
• 31 Crossley IR, Bihari D, Gimson AES, Westaby D, Richardson PJ, Williams R. Effects of converting enzyme inhibitor on hepatic blood flow in man. Am J Med 1984; 31: 62-65
• 32 Shepherd AN, Hayes PC, Jacyna M, Morrison L, Bouchier IAD. The influence of captopril, the nitrates and propranolol on apparent liver blood flow. Br J Clin Pharmac 1985; 19: 393-397